• O-GlcNAcylation Rewires Glycolysis in Bone Formation

  2026-10-05

  You et al. identify O-GlcNAcylation as a mechanistic link between Wnt signaling, aerobic glycolysis, and osteoblast-driven bone formation. The study places PDK1 Ser174 modification at the center of this pathway while showing that loss of osteoblast-lineage O-GlcNAcylation weakens Wnt-stimulated bone formation and fracture healing.

• DCFH-DA in Oxidative Stress Research

  2026-10-05

  2,7-Dichlorodihydrofluorescein diacetate, commonly called DCFH-DA, is a cell-permeable fluorogenic probe used to study intracellular oxidative signals. This overview examines its conceptual value and limitations through the reported findings of a 2026 rat granulosa-cell study of LSKL, THBS1, oxidative stress, and PCOS-related ovarian dysfunction.

• Rosiglitazone and Beige Fat Research Context

  2026-10-04

  This overview places Rosiglitazone, also known as Brl-49653, within research on PPARγ activation in adipogenesis, insulin sensitivity modulation, and beige adipocyte biology. It compares the compound’s receptor-centered research role with new mouse evidence linking SEMA3E to β-catenin signaling, oxidative phosphorylation, and thermogenesis, while defining the study’s limitations and translational boundaries.

• CD44 Metabolic Rewiring in IDH-Mutant Leukemia

  2026-10-03

  A 2025 Blood study identifies CD44 as a metabolic dependency in IDH-mutant leukemia, linking adhesion biology to NADPH production and sustained R-2HG generation. Its findings suggest that combining mutant-IDH inhibition with disruption of CD44-associated metabolic rewiring may address limitations of single-agent treatment, although validation beyond the reported models remains necessary.

• AZD1480 and the Tumor-Protective JAK2/STAT3 Axis

  2026-10-02

  AZD1480 offers translational researchers a precise way to interrogate tumor-intrinsic JAK2/STAT3 signaling after IDO1 blockade. This thought-leadership perspective connects pathway pharmacology with compartment-resolved assays, combination design, biomarker strategy, and the limits of translating immune activation into durable tumor control.

• AZD2461: Rethinking PARP Inhibitor Translation

  2026-10-01

  AZD2461 offers a useful translational model for connecting PARP-1 inhibition, DNA repair vulnerability, resistance biology, and more informative in vitro drug-response measurements.

• Palbociclib Nanocrystals in a Thermoresponsive Gel

  2026-10-01

  The reference study combines palbociclib nanocrystals with a thermoresponsive poloxamer gel to improve dissolution, local retention, and anticancer activity against breast cancer cells. Its findings support a formulation strategy for localized CDK4/6 inhibitor delivery, while the in vitro design leaves important questions about intratumoral distribution, systemic exposure, and clinical translation.

• Lypressin Acetate: From Receptor Biology to Assay Design

  2026-09-30

  Lypressin acetate links a defined vasopressin-receptor pharmacology with practical decisions in antidiuretic, vasoconstriction, and antiviral research. This article presents an assay-centered framework for interpreting potency, exposure, receptor bias, and emerging SARS-CoV-2 RdRp hypotheses without overstating translational evidence.

• AZD1480: Mapping Tumor-Intrinsic STAT3 Escape

  2026-09-30

  Explore how the JAK2 inhibitor AZD1480 can dissect tumor-intrinsic STAT3 survival after IDO1 blockade. This article emphasizes compartment-aware assays, causal controls, and translational limits rather than repeating standard compound workflows.

• Azithromycin: Workflows for Infection and Senolysis

  2026-09-29

  Azithromycin supports distinct research workflows, from resistance benchmarking and bacterial infection research to senescent-fibroblast screening. This guide connects its ribosome-directed activity with practical assay design, solvent control, impurity monitoring, and translational limitations.

• Lypressin Acetate: A Mechanism-to-Assay Guide

  2026-09-29

  Lypressin acetate is a multifunctional vasopressin receptor agonist whose receptor profile can guide better antidiuretic, vasoconstriction, and antiviral assay design. This mechanism-to-assay perspective connects molecular identity, endpoint selection, handling, and evidence maturity.

• M. pneumoniae Resistance in Beijing Children, 2023

  2026-09-28

  This 2024 study linked phenotypic susceptibility testing with molecular typing and clinical data to characterize macrolide-resistant Mycoplasma pneumoniae in children from Beijing. All 62 isolates carried the A2063G mutation and were resistant to erythromycin and azithromycin, emphasizing the need for local surveillance and non-macrolide treatment research.

• gamma-Glu-Cys Workflows for Glutathione Research

  2026-09-28

  Use gamma-Glu-Cys (γ-Glu-Cys) to probe glutathione synthesis directly, then pair substrate-controlled assays with carefully matched microbial or plant experiments. The key is to separate what a defined enzyme assay can establish from what whole-cell peptide production depends on: strain, medium, and substrate availability.

• Beyond DNA Repair: Mapping ATM Inhibition

  2026-09-27

  ATM inhibition can reshape more than DNA damage signaling. Explore how AZD0156 supports selective ATM kinase research and how to test the emerging link between DNA damage response, nutrient scavenging, and cancer cell adaptation.

• Cabozantinib (XL184) Workflows for RCC Signaling

  2026-09-26

  Use Cabozantinib (XL184) to compare acute kinase suppression with chronic signaling adaptation in cancer models—not just to measure short-term growth effects. This practical guide connects phosphoproteomics, motility assays, and antiangiogenic readouts while highlighting controls that help distinguish drug response from adaptation.

8124 records 1/542 page Next 12345 下5页 Last page